(Sharecast News) - Shore Capital has reiterated its 'buy' rating on GSK after the biopharma giant's latest update about its ongoing Zantac litigation, saying that the stock's valuation is still undemanding compared with the wider market.
GSK welcomed a decision from the Delaware Supreme Court to review a lower court ruling...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE